Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with A
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q2 2022 | ANHYDROUS CITRIC ACID | BUCCAL | FILM, SOLUBLE | 3mg | Correction | ||
| Q3 2022 | ANHYDROUS CITRIC ACID | BUCCAL | FILM, SOLUBLE | 2mg | Correction | ||
| Q3 2022 | ACETYLTRIBUTYL CITRATE | ORAL | TABLET, COATED PARTICLES | 18.70 mg | 150mg | Deletion | |
| Q3 2022 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | CAPSULE, DELAYED RELEASE | 381.00 mg | 381mg | Deletion | |
| Q2 2022 | ACETYLTRIBUTYL CITRATE | ORAL | TABLET | 0.56 mg | MDE Replacement | ||
| Q3 2022 | ACETYLTRIBUTYL CITRATE | ORAL | TABLET | 150mg | MDE Replacement | ||
| Q2 2022 | ACRYLIC ADHESIVE 788 | TRANSDERMAL | SYSTEM | 44.91 mg | MDE Replacement | ||
| Q3 2022 | ACRYLIC ADHESIVE 788 | TRANSDERMAL | SYSTEM | 45mg | MDE Replacement | ||
| Q2 2022 | ALCOHOL | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 7960.00 mg | MDE Replacement | ||
| Q3 2022 | ALCOHOL | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 31840mg | MDE Replacement | ||
| Q2 2022 | ANHYDROUS CITRIC ACID | BUCCAL | FILM | 1.04 mg | MDE Replacement | ||
| Q3 2022 | ANHYDROUS CITRIC ACID | BUCCAL | FILM | 9mg | MDE Replacement | ||
| Q2 2022 | ANHYDROUS CITRIC ACID | ORAL | PASTE | 0.85 mg/ 1.00 ml | MDE Replacement | ||
| Q3 2022 | ANHYDROUS CITRIC ACID | ORAL | PASTE | 26mg | MDE Replacement | ||
| Q2 2022 | ANHYDROUS CITRIC ACID | TOPICAL | CLOTH | 4.20 mg | MDE Replacement | ||
| Q3 2022 | ANHYDROUS CITRIC ACID | TOPICAL | CLOTH | 4mg | MDE Replacement | ||
| Q2 2022 | ANHYDROUS TRISODIUM CITRATE | SUBLINGUAL | FILM | 1.34 mg | MDE Replacement | ||
| Q3 2022 | ANHYDROUS TRISODIUM CITRATE | SUBLINGUAL | FILM | 4mg | MDE Replacement | ||
| Q2 2022 | ANISE | ORAL | SOLUTION | 5.00 mg/ 5.00 ml | MDE Replacement | ||
| Q3 2022 | ANISE | ORAL | SOLUTION | 72mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 1, 2022
Database Last Updated: July 18, 2022